ASP6432

Cat. No.: HY-120478

CAS No.: 1282549-08-9

Molecular Formula: $C_{26}H_{31}KN_4O_6S_2$

Molecular Weight: 598.78

Target: LPL Receptor

Pathway: GPCR/G Protein

Storage: 4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

DMSO : 250 mg/mL (417.52 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	1.6701 mL	8.3503 mL	16.7006 mL
	5 mM	0.3340 mL	1.6701 mL	3.3401 mL
	10 mM	0.1670 mL	0.8350 mL	1.6701 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 4.17 mg/mL (6.96 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 4.17 mg/mL (6.96 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

ASP6432 is a potent and selective type 1 lysophosphatidic acid receptor (LPA1) antagonist with IC_{50}s of 11 nM and 30 nM for human LPA1 and rat LPA1, respectively[1].

IC_{50} & Target

IC50: 11 nM (human LPA1), 30 nM (rat LPA1)[1]

In Vitro

ASP6432 inhibits the LPA-induced proliferation of human prostate stromal cells[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Sakamoto K, et al. Effect of ASP6432, a Novel Type 1 Lysophosphatidic Acid Receptor Antagonist, on Urethral Function and Prostate Cell Proliferation. J Pharmacol Exp Ther. 2018 Aug;366(2):390-396.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA